Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RFR014
MIFTS: 18

Refractory Anemia with Excess Blasts Type 2

Categories: Blood diseases, Rare diseases
Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Refractory Anemia with Excess Blasts Type 2

About this section

MalaCards integrated aliases for Refractory Anemia with Excess Blasts Type 2:

Name: Refractory Anemia with Excess Blasts Type 2 58
Refractory Anemia with Excess Blasts Ii 71
Raeb-2 58

Characteristics:

Orphanet epidemiological data:

58
refractory anemia with excess blasts type 2
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D46.2
UMLS via Orphanet 72 C1318551
Orphanet 58 ORPHA100020
UMLS 71 C1318551
Sources

Summaries for Refractory Anemia with Excess Blasts Type 2

About this section
MalaCards based summary : Refractory Anemia with Excess Blasts Type 2, also known as refractory anemia with excess blasts ii, is related to leukemia, acute myeloid and myeloid leukemia. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone.

Sources

Related Diseases for Refractory Anemia with Excess Blasts Type 2

About this section

Diseases in the Refractory Anemia with Excess Blasts Type 2 family:

Refractory Anemia with Excess Blasts Type 1

Diseases related to Refractory Anemia with Excess Blasts Type 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 10.3
2 myeloid leukemia 10.3
3 myelodysplastic syndrome 10.2
4 ecthyma 10.2
5 myelodysplastic syndrome with excess blasts 10.2
6 refractory anemia 10.2
7 fanconi anemia, complementation group a 10.1
8 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
9 deficiency anemia 10.1
10 neutropenia 10.1
11 pancytopenia 10.1
12 pneumonia 10.1
13 myeloid sarcoma 10.1

Graphical network of the top 20 diseases related to Refractory Anemia with Excess Blasts Type 2:



Diseases related to Refractory Anemia with Excess Blasts Type 2
Sources

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts Type 2

About this section
Sources

Drugs & Therapeutics for Refractory Anemia with Excess Blasts Type 2

About this section

Drugs for Refractory Anemia with Excess Blasts Type 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
3
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
4
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
5
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
6
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
7
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
8
Daunorubicin Approved Phase 3 20830-81-3 30323
9
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
10
Etoposide Approved Phase 3 33419-42-0 36462
11 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
12 Adjuvants, Immunologic Phase 2, Phase 3
13 Alkylating Agents Phase 2, Phase 3
14 Antirheumatic Agents Phase 2, Phase 3
15 Immunosuppressive Agents Phase 3
16 Immunologic Factors Phase 3
17 Antimetabolites Phase 3
18 Anti-Infective Agents Phase 3
19 Anti-Bacterial Agents Phase 3
20 Antiviral Agents Phase 3
21 Antibiotics, Antitubercular Phase 3
22 Protein Kinase Inhibitors Phase 3
23 ON 01910 Phase 3
24 Etoposide phosphate Phase 3
25
Idarubicin Approved Phase 1, Phase 2 58957-92-9 42890
26
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
27 Angiogenesis Inhibitors Phase 1, Phase 2
28 Vaccines Phase 1
29 Antimitotic Agents Phase 1
30 Aclacinomycins

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
2 A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
3 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
4 AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00703820 Phase 3 Cytarabine;Daunorubicin;Etoposide;Clofarabine
5 A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia Active, not recruiting NCT00831766 Phase 1, Phase 2 Idarubicin;Cytarabine;Lenalidomide (Revlimid®)
6 A Phase I Study of B7.1 (CD80)/IL-2 Immune Gene Therapy for High Risk MDS RAEB-2 and Acute Myeloid Leukaemia Patients Unsuitable for Allogeneic Haematological Stem Cell Transplant Unknown status NCT02493829 Phase 1
7 Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies Completed NCT01139151 Phase 1 3 Day Thiarabine;5 Day Thiarabine
8 A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8 Completed NCT00533416 Phase 1 ON 01910 Na
9 Effect of Chemotherapy vs No Chemotherapy Pre-transplantation for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS (Bone Marrow Blast Cells Less Than 50%) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT02850822 Demethylation drug;Chemotherapy regimen

Search NIH Clinical Center for Refractory Anemia with Excess Blasts Type 2

Sources

Genetic Tests for Refractory Anemia with Excess Blasts Type 2

About this section
Sources

Anatomical Context for Refractory Anemia with Excess Blasts Type 2

About this section

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts Type 2:

40
Myeloid, Bone Marrow, Bone
Sources

Publications for Refractory Anemia with Excess Blasts Type 2

About this section

Articles related to Refractory Anemia with Excess Blasts Type 2:

# Title Authors PMID Year
1
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. 61
32469434 2020
2
Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome-Refractory anemia with excess blasts type 2. 61
31534742 2019
3
p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation. 61
28588781 2017
4
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. 61
24440648 2014
5
Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review. 61
24646765 2014
6
[Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance]. 61
22739171 2012
7
Quantitation of human herpesvirus-6 (HHV-6) DNA in a cord blood transplant recipient with chromosomal integration of HHV-6. 61
22093262 2011
8
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. 61
19528370 2009
9
Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II. 61
19236759 2009
Sources

Variations for Refractory Anemia with Excess Blasts Type 2

About this section
Sources

Expression for Refractory Anemia with Excess Blasts Type 2

About this section
Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts Type 2.
Sources

Pathways for Refractory Anemia with Excess Blasts Type 2

About this section
Sources

GO Terms for Refractory Anemia with Excess Blasts Type 2

About this section
Sources

Sources for Refractory Anemia with Excess Blasts Type 2

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....